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Suzhou, China
Objectives Our goal was to evaluate the association between erectile dysfunction (ED) and risk of cardiovascular disease
(CVD) and all-cause mortality by conducting a meta-analysis of prospective cohort studies.
Background Observational studies suggest an association between ED and the incidence of CVD. However, whether ED is an
independent risk factor of CVD remains controversial.
Methods The PubMed database was searched through January 2011 to identify studies that met pre-stated inclusion cri-
teria. Reference lists of retrieved articles were also reviewed. Two authors independently extracted information
on the designs of the studies, the characteristics of the study participants, exposure and outcome assessments,
and control for potential confounding factors. Either a fixed- or a random-effects model was used to calculate
the overall combined risk estimates.
Results Twelve prospective cohort studies involving 36,744 participants were included in the meta-analysis. The overall
combined relative risks for men with ED compared with the reference group were 1.48 (95% confidence interval
[CI]: 1.25 to 1.74) for CVD, 1.46 (95% CI: 1.31 to 1.63) for coronary heart disease, 1.35 (95% CI: 1.19 to 1.54)
for stroke, and 1.19 (95% CI: 1.05 to 1.34) for all-cause mortality. Sensitivity analysis restricted to studies with control
for conventional cardiovascular risk factors yielded similar results. No evidence of publication bias was observed.
Conclusions This meta-analysis of prospective cohort studies suggests that ED significantly increases the risk of CVD,
coronary heart disease, stroke, and all-cause mortality, and the increase is probably independent of conven-
tional cardiovascular risk factors. (J Am Coll Cardiol 2011;58:1378–85) © 2011 by the American College
of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.024Erectile dysfunction (ED) is common and increases as men
age. It is estimated that approximately 18 million men in
United States currently experience ED (1). Meanwhile,
cardiovascular disease (CVD) remains the leading cause of
death in the United States (2). It is well accepted that CVD
predicts incidence of ED, largely because both conditions
share the same risk factors, including age, hypertension,
dyslipidemia, smoking, obesity, and diabetes (3). Con-
versely, it has also been hypothesized that ED may be a
marker of further cardiovascular events (4).
The past few years have seen a rapidly growing interest in
testing this hypothesis. Many epidemiologic studies (5–21)
have investigated the link between ED and risk of CVD, and
most found a positive association. However, the magnitudes of
the association varied between studies. Although a previous
meta-analysis (22) combined several cohort studies and re-
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accepted June 7, 2011.ported a statistically significant relation of ED to cardiovascular
risk, evidence was limited because only 7 cohort studies were
available at that time. Of note, 2 of the 7 cohort studies used
a retrospective cohort design, which suffers more confounding
and biases than a prospective cohort design. Furthermore,
whether ED is an independent risk factor or merely a silent
marker of CVD remains unclear. An improved understanding
of this issue may have important public health and clinical
implications given the possibility that prevention and treat-
ment of ED might reduce the incidence of cardiovascular
events. With recently accumulating evidence, our goal, there-
fore, was to evaluate the association between ED and risk of
CVD and all-cause mortality by conducting a meta-analysis of
prospective cohort studies.
Methods
Search strategy. We attempted to follow the proposed
MOOSE (Meta-Analysis of Observational Studies in Epi-
demiology) (23) guidelines to report the present meta-
analysis. We conducted a PubMed database search through
January 2011 for relevant studies that tested the association
between ED and risk of CVD, coronary heart disease
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terms were used: 1) cardiovascular diseases, coronary dis-
ease, coronary thrombosis, myocardial ischemia, myocardial
infarction, coronary stenosis, coronary restenosis, cerebro-
vascular disorders, stroke, death, mortality, and all-cause
mortality; 2) erectile dysfunction, sexual dysfunction, and
impotence; and 3) cohort studies, prospective studies, and
follow-up studies. No restrictions were imposed. In addi-
tion, we reviewed the reference lists of retrieved papers and
recent reviews.
Study selection. We first performed an initial screening
of titles or abstracts. A second screening was based on
full-text review. Studies were considered eligible if they
met the following criteria: 1) the study design was a
prospective cohort study; 2) the exposure of interest was ED;
3) the outcome of interest was CVD, CHD, stroke, or
all-cause mortality; and 4) relative risk (RR) and the corre-
sponding 95% confidence interval (CI) (or data to calculate
them) were reported.
Data extraction. The key exposure variable was the pres-
ence or absence of ED at baseline. In most studies, men
without ED served as the reference group, although in 3
studies (12,18,20), men with minimal or mild ED served as
the reference group. We included all these studies for
meta-analysis and performed a sensitivity analysis that only
included studies with a reference group defined as strictly
non-ED men.
Outcomes of interest in this study included major CVD
(fatal and nonfatal), CHD (fatal and nonfatal), stroke (fatal
and nonfatal), and all-cause mortality. CVD were defined as
CHD, stroke, cardiac arrest, heart failure, peripheral artery
disease, and sudden death. CHD was defined as acute
myocardial infarction, angina pectoris, and other ischemic
heart disease.
Data extraction was then performed using a standard-
ized data-collection form. We extracted any reported
RRs, hazard ratios, or incidence density ratios of out-
comes for patients with ED compared with the reference
group. We also extracted study characteristics for each
trial. Data were recorded as follows: first author’s last
name; year of publication; country of origin; study period
and duration of follow-up; characteristics of study pop-
ulation and age at baseline; number of CVD, CHD,
stroke, or all-cause mortality events and total partici-
pants; ascertainments of ED; assessments of outcomes;
and statistical adjustments for confounding factors. Two
authors (J.-Y.D. and L.-Q.Q.) independently conducted
the studies selection and data extraction. Any disagree-
ments were resolved by discussion.
Statistical analyses. RR was used as a common measure of
the association between ED and risk of CVD, CHD,
stroke, or all-cause mortality across studies. The hazard
ratios and incidence density ratios were directly considered
as RRs. We calculated RRs for one study (19) in which only
age-adjusted incidence rates for each group were reported.
For another study (11) that reported hazard ratios separately ffor reduced erectile rigidity and
severely reduced erectile rigidity,
we combined these 2 groups into
a single group and calculated a
combined hazard ratio using a
fixed-effects model for the main
analysis. RRs and corresponding
SEs, which were derived from
95% CIs or p values, were loga-
rithmically transformed to stabi-
lize variance and normalize the
distribution (24).
Homogeneity of RRs across studies was tested by using
the Q statistic (significance level at p  0.10). The I2
statistic, which is a quantitative measure of inconsistency
across studies (25), was also calculated. The combined risk
estimates were computed using either fixed-effects models
or, in the presence of heterogeneity, random-effects models
(26). Because characteristics of populations, ascertainment
of ED, and adjustments for confounding factors were not
consistent between studies, we further conducted a sensitiv-
ity analysis to explore possible explanations for heterogene-
ity and to examine the influence of various exclusion criteria
on the overall risk estimate. We also investigated the
influence of a single study on the overall risk estimate by
omitting 1 study in each turn. The sensitivity analysis was
only performed for CVD because of rather small numbers of
studies for other outcomes.
Potential publication bias was assessed by visual inspec-
tion of the Begg funnel plots in which the log RRs were
plotted against their SEs. We also performed the Begg rank
correlation test and Egger linear regression test at the p 0.10
evel of significance (27,28). All analyses were performed
sing STATA version 11.0 (StataCorp LP, College Station,
exas). A p value 0.05 was considered statistically signif-
cant, except where otherwise specified.
esults
iterature search. We initially retrieved 633 unique citations
rom the PubMed database. Of these, the majority were
xcluded after the first screening based on abstracts or titles,
ainly because they were reviews, case-control studies, cross-
ectional studies, or not relevant to our analysis. After full-text
eview of 19 papers, 4 studies (5,6,8,17) were excluded because
hey used a retrospective cohort design. An additional 3 studies
29–31) in which the association of interest was not evaluated
ere excluded. Finally, 12 studies (7,9–13,15,16,18–21) were
ncluded in our meta-analysis. A flow chart showing the study
election is presented in Figure 1.
tudy characteristics. The characteristics of the 12 pro-
pective cohort studies are presented in Table 1. These
tudies were published between 2005 and 2011. Five studies
ere conducted in the United States, 4 in Europe, 2 in
hina, and 1 was a multicountry study. The mean length of
Abbreviations
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CHD  coronary heart
disease
CI  confidence interval
CVD  cardiovascular
disease
ED  erectile dysfunction
RR  relative riskollow-up ranged from 4 to 16.2 years. Three studies were
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ranged from 291 to 9,006 (total 36,744). The ascertainment
of ED varied across studies, with most based on self-report
or interviewer-administered questionnaires. Among the 12
studies included here, 8 reported CVD events, 4 reported
CHD events, 3 reported stroke events, and 3 reported
all-cause mortality. Outcome assessments were from a
variety of sources, including medical record, self-report, and
hospital database. Two studies adjusted for age only,
whereas others controlled a group of conventional risk
factors for CVD, including age, body mass index, blood
pressure, diabetes, cholesterol, and smoking.
ED and risk of CVD. Figure 2 shows the results from the
andom-effects model combining the RRs for CVD.
mong the 8 studies, 7 showed a significantly positive
elation between ED and risk of CVD. However, the RRs
or the association varied from 0.92 to 2.10 across studies.
verall, men with ED compared with the reference group
xperienced a significantly increased risk for developing CVD
RR: 1.48 [95% CI: 1.25 to 1.74]; p  0.001). Substantial
eterogeneity was observed (p  0.001, I2  72.9%).
ED and risk of CHD, stroke, and all-cause mortality.
Figure 3 presents the results from fixed-effects models
combining the RRs for CHD, stroke, and all-cause mor-
tality. Although there were fewer studies for these outcomes
than CVD, the results were relatively consistent. The overall
combined RRs in relation to ED were 1.46 (95% CI: 1.31
to 1.63; p  0.001) for CHD, 1.35 (95% CI: 1.19 to 1.54;
Figure 1 Flow Chart of Study Selection
Flow chart shows literature search for prospective cohort studies of
erectile dysfunction in relation to cardiovascular events and all-cause mortality.p  0.001) for stroke, and 1.19 (95% CI: 1.05 to 1.34; p 0.005) for all-cause mortality. There was no evidence of
heterogeneity for these outcomes (all p values  0.40, all I2
values  0%). Further analyses using the random-effects
model yielded identical results.
Sensitivity analyses. Sensitivity analyses were conducted to
explore potential sources of heterogeneity in the association
between ED and CVD and to examine the influence of
various exclusion criteria on the overall risk estimate. Ex-
clusion of 2 studies (18,19) in which men with minimal or
mild ED served as the reference group yielded similar
results (RR: 1.46 [95% CI: 1.20 to 1.78]; p  0.001), with
substantial evidence of heterogeneity (p  0.001, I2 
79.6%). Exclusion of 2 studies (19,20) that adjusted only for
age showed a somewhat greater risk (RR: 1.54 [95% CI:
1.28 to 1.87]; p 0.001), yet heterogeneity was still present
(p  0.001, I2  79%). Exclusion of 2 studies (9,16) that
enrolled patients with diabetes changed the overall risk
estimate little (RR: 1.47 [95% CI: 1.32 to 1.64]; p 0.001),
but no evidence of heterogeneity was observed among the
remaining studies (p  0.45, I2  0%). Further exclusion of
any single study did not materially alter the overall com-
bined RR, with a range from 1.38 (95% CI: 1.21 to 1.59;
p  0.001) to 1.56 (95% CI: 1.34 to 1.83; p  0.001).
Publication bias. Visual inspection of the Begg funnel plot
did not identify substantial asymmetry. The Begg rank
correlation test and Egger linear regression test also indi-
cated no evidence of publication bias among studies of ED
and CVD risk (Begg, p  0.81; Egger, p  0.24).
Discussion
There is rapidly growing interest in the association between
ED and risk of CVD. Our meta-analysis of 12 prospective
cohort studies provides evidence that ED is significantly and
independently associated with an increased risk of CVD,
CHD, stroke, and all-cause mortality. Men with ED,
compared with the reference group, experienced a signifi-
cantly increased risk of 48% for CVD, 46% for CHD, 35%
for stroke, and 19% for all-cause mortality.
ED as an independent risk factor of CVD. At present,
the association between ED and CVD is not fully under-
stood. It is well accepted that CVD is a risk factor of ED
(3). It is also recognized that ED is a marker of further
vascular diseases (32). However, whether ED is indepen-
dently associated with incidence of CVD remains contro-
versial. Results from our sensitivity analysis restricted to
studies (7,9,11,15,16,18) with control for conventional car-
diovascular risk factors, including age, body mass index,
blood pressure, diabetes, cholesterol, and smoking, suggest
that ED is probably an independent risk factor of CVD.
Moreover, if ED was merely an early marker, it would be
more likely to occur near the time of onset of cardiovascular
events. In fact, the mean length of follow-up in primary
studies ranged from 4 to 16 years. Such a large interval
between the 2 diseases further supports the hypothesis that
ED is an independent risk factor.
Characteristics of 12 Prospective Cohort Studies of ED and Cardiovascular Events and All-Cause MortalityTable 1 Characteristics of 12 Prospective Cohort Studies of ED and Cardiovascular Events and All-Cause Mortality
First Author,
Year (Ref. #) Location/Period
Duration
(yrs) Population Assessment of ED Outcomes Adjustment for Covariates
Thompson et al.,
2005 (7)
United States,
1994–2003
7.0 8,063 men; age 55 yrs Self-report questionnaire CVD, CHD, stroke,
and all-cause
mortality
Age, BMI, blood pressure, TC, HDL-C, diabetes, family history of
myocardial infarction, race, current smoking, current use of
antihypertensive medication, physical activity, and global and
self-reported health status
Gazzaruso et al.,
2008 (9)
Italy, 1998–2006 4.0 291 diabetic patients;
mean age 54.8 yrs
IIEF-5 questionnaire CVD Age, diabetes duration, hypertension, family history of CHD, smoking,
microalbuminuria, glycated hemoglobin, BMI, TC, TG, LDL-C, HDL-C,
and autonomic dysfunction
Ma et al.,
2008 (10)
Hong Kong of China,
1995–2005
4.0 2,306 diabetic patients;
mean age 54.2 yrs
Interview CHD Age, duration of diabetes, albuminuria, and use of
antihypertensive medications
Schouten et al.,
2008 (11)
the Netherlands,
1994–2003
6.3 1,248 men; age 50–75 yrs Self-report questionnaire CVD Age, smoking, HDL-C, cholesterol, SBP, and diabetes
Araujo et al.,
2009 (12)
United States,
1989–2004
15.0 1,709 men; age 40–70 yrs Interviewer-administered
questionnaire
All-cause
mortality
Age, smoking, HDL-C, SBP, race, waist circumference,
alcohol consumption, physical activity, self-assessed health, and
self-reported chronic disease
Inman et al.,
2009 (13)
United States,
1996–2005
10.0 1,402 men; age 40–79 yrs Self-report questionnaire CHD Age, BMI, diabetes, hypertension, and history of smoking
Araujo et al.,
2010 (15)
United States,
1989–2004
11.7 1,057 men; age 40–70 yrs Interviewer-administered
questionnaire
CVD Age, BMI, HDL-C, TC, smoking, and hypertension
Batty et al.,
2010 (16)
Multiple countries,
2001–2007
5.0 6,304 diabetic patients;
age 55–88 yrs
Interview CVD, CHD, stroke,
and all-cause
mortality
Age, BMI, use of metformin or beta-blockers, history of macrovascular
or microvascular disease, diabetes duration, smoking,
alcohol intake, physical activity, glycated hemoglobin, creatinine, TC,
HDL-C, resting heart rate, blood pressure, and education
Corona et al.,
2010 (18)
Italy, 2000–2007 4.3 1,687 men; age 17–88 yrs Structured interview CVD Age and Chronic Diseases Score
Hall et al.,
2010 (19)
United States,
1987–2004
16.2 1,165 men; age 40-70 yrs Self-report questionnaire CVD Age
Ponholzer et al.,
2010 (20)
Austria, 2001–2008 6.5 2,506 men; age 20–80 yrs IIEF-5 questionnaire CVD Age
Chung et al.,
2011 (21)
Taiwan of China,
1996–2006
5.0 9,006 men; age 40 yrs Clinical diagnosis Stroke Age, income, geographical location, hypertension, peripheral vascular
disease, diabetes, CHD, atrial fibrillation, and hyperlipidemia
BMI body mass index (calculated as weight in kilograms divided by height in meters squared); CHD coronary heart disease; CVD cardiovascular disease; ED erectile dysfunction; HDL-C high-density lipoprotein cholesterol; IIEF-5 5 item version of the International
Index of Erectile Function; LDL-C  low-density lipoprotein cholesterol; SBP  systolic blood pressure; TC  total cholesterol; TG  total triglycerides.
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between ED and CVD are uncertain. One possible expla-
nation is the “artery size hypothesis” (33). According to this
hypothesis, because atherosclerosis affects all major vascular
beds to the same extent, penile arteries, which are smaller in
diameter than coronary arteries, are affected earlier by the
same size of atherosclerotic plaque and hence ED manifests
before cardiovascular events. Another explanation is endo-
thelial dysfunction, a shared etiologic factor of both diseases
(34). Endothelial dysfunction without atherosclerotic
plaque narrowing the penile arteries is more likely to lead to
ED than the case in the coronary arteries leading to angina
(35). In addition, there may be a smooth muscle dysfunction
beyond the endothelial dysfunction in patients with ED,
which can occur before onset of systemic vascular diseases
(36). However, these theories cannot explain an indepen-
dent role of ED in the development of CVD. Depression,
an important risk factor of CHD (37), may lie on the
pathway between ED and CVD. ED and depression are
known to be strongly correlated (38). A population-based,
prospective cohort study has provided evidence that ED
may independently increase depression risk (39). As a result,
men with ED experience a higher risk of depression and
hence an increased risk of subsequent cardiovascular events
than those free of it. It should be noted that observational
studies cannot prove causality. However, our study meets
several of the Hill criteria (40) for causation. First, there was
a clear temporal relationship: ED preceded the onset of
Figure 2 ED and Risk of CVD
Forest plot shows association between erectile dysfunction (ED) and risk of cardioCVD in all primary studies. Second, the strength of theassociation with ED is not negligible and somewhat com-
parable to that of conventional cardiovascular risk factors,
including diabetes, hypertension, smoking, and obesity (13).
Third, the positive association was broadly consistent across
different studies and among various populations. Fourth,
there is a dose-response effect. Several studies (11,14,18)
have observed the risk of CVD increasing when ED
symptoms are severe. Finally, plausible biological explana-
tions exist, as noted previously.
Sources of heterogeneity. Substantial heterogeneity was
observed among studies of ED and CVD risk, which was
not surprising given the differences in characteristics of
populations, ascertainment of ED, and adjustment for
confounding factors. Our sensitivity analyses suggest that 2
studies (9,16) conducted in patients with diabetes probably
contributed to the heterogeneity. In addition to differences
in features of study populations, these 2 studies also differed
from others in some aspects. For one study (9), the small
number of cases and participants increased the possibility
that chance accounted for their results. For another study (16),
participants were categorized as ED or non-ED patients
through a simple question asked by nurses, which may lead to
misclassification bias and hence underestimated results. In
fact, the RR reported by that study (16) was evidently
smaller than others.
Study strengths and limitations. A major strength of our
study is that all the included original studies used a
prospective cohort design, which eliminates the possibility
ar diseases (CVDs). CI  confidence interval; RR  relative risk.vasculof reverse causation (i.e., the presence of CVD might have
1383JACC Vol. 58, No. 13, 2011 Dong et al.
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association of ED with risk of CVD persists and remains
statistically significant in sensitivity analyses based on vari-
ous exclusion criteria. In addition, with the accumulating
evidence and enlarged sample size, we have enhanced
statistical power to provide more precise and reliable risk
estimates.
One potential limitation of the present meta-analysis was
the various assessments of ED used between studies. The
International Index of Erectile Function questionnaire,
which was developed and validated in 1996 to 1997 (41),
has been adopted as the gold standard measure for efficacy
assessment of ED (42). However, this questionnaire was not
used in most included studies because they were initiated
before its introduction. One advantage of this questionnaire
is that it captures information on the severity of ED, which
provides the opportunity to examine dose-response effects.
Conversely, the absence of such a validated questionnaire
increases the likelihood of misclassification bias, thereby
underestimating the strength of the association. For in-
stance, interview may result in underdiagnosis of ED
because of embarrassment by patients and their reluctance
Figure 3 ED and Risk of CHD, Stroke, and All-Cause Mortality
Forest plots show associations between ED and risk of coronary heart disease (CHto discuss the topic.A second limitation is the substantial heterogeneity
among studies for the association between ED and risk of
CVD. Nevertheless, we were able to detect the major source
of heterogeneity through the sensitivity analyses. In addi-
tion, residual confounding is of concern. Uncontrolled or
unmeasured risk factors potentially produce biases. Al-
though restricting analysis to studies (7,9,11,15,16,18) that
adjusted for a group of conventional cardiovascular risk
factors did not materially alter the combined risk estimate,
we still cannot rule out the possibility that residual con-
founding could affect the results because these factors do not
explain all of the risk for cardiovascular events (43). Fur-
thermore, because current data in relation to ED and
outcomes for CHD, stroke, and all-cause mortality are
sparse, we were unable to investigate stroke subtypes and
CVD mortality. Nevertheless, results for these outcomes
were consistent. Finally, although little evidence of publi-
cation bias was observed, the statistical power for these tests
was limited due to a relatively small number of included
studies.
Suggestions for further studies. On the basis of our
findings, several questions arise. First, is the association of
roke, and all-cause mortality. Abbreviations as in Figure 2.D), stED with CVD causal? To answer this question, several
22
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questionnaire (41), the interval between the incidence of the
2 diseases, and adequate control for confounding factors.
Second, by what exact mechanisms does ED independently
increase the risk of CVD? Psychological factors, such as
anxiety and depression, may offer insights. Third, could
treating ED through drug intervention, lifestyle modifica-
tion, and/or dietary therapy protect against cardiovascular
events? A similar question was posed by the landmark report
(7) in 2005, but it remains unanswered to date. Further
studies, including well-designed clinical trials, are warranted
to address these questions for a better understanding of the
association and to provide convincing evidence for clinical
practice in CVD prevention.
Conclusions
This meta-analysis of prospective cohort studies suggests
that ED significantly increases the risk of CVD, CHD,
stroke, and all-cause mortality, and the increase is probably
independent of conventional cardiovascular risk factors.
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